Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 318

1.

Oral fluid cannabinoids in chronic cannabis smokers during oral δ9-tetrahydrocannabinol therapy and smoked cannabis challenge.

Lee D, Vandrey R, Mendu DR, Anizan S, Milman G, Murray JA, Barnes AJ, Huestis MA.

Clin Chem. 2013 Dec;59(12):1770-9. doi: 10.1373/clinchem.2013.207316. Epub 2013 Aug 12.

2.

Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking.

Lee D, Vandrey R, Mendu DR, Murray JA, Barnes AJ, Huestis MA.

Drug Test Anal. 2015 Jun;7(6):494-501. doi: 10.1002/dta.1718. Epub 2014 Sep 14.

3.

Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?

Lee D, Karschner EL, Milman G, Barnes AJ, Goodwin RS, Huestis MA.

Drug Alcohol Depend. 2013 Jun 1;130(1-3):68-76. doi: 10.1016/j.drugalcdep.2012.10.011. Epub 2012 Nov 10.

4.

Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence.

Lee D, Milman G, Barnes AJ, Goodwin RS, Hirvonen J, Huestis MA.

Clin Chem. 2011 Aug;57(8):1127-36. doi: 10.1373/clinchem.2011.164822. Epub 2011 Jun 15.

5.

Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.

Milman G, Bergamaschi MM, Lee D, Mendu DR, Barnes AJ, Vandrey R, Huestis MA.

Ther Drug Monit. 2014 Apr;36(2):218-24. doi: 10.1097/FTD.0b013e3182a5c446.

6.

Cannabinoid disposition in oral fluid after controlled smoked cannabis.

Lee D, Schwope DM, Milman G, Barnes AJ, Gorelick DA, Huestis MA.

Clin Chem. 2012 Apr;58(4):748-56. doi: 10.1373/clinchem.2011.177881. Epub 2012 Jan 24.

7.

Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers.

Anizan S, Milman G, Desrosiers N, Barnes AJ, Gorelick DA, Huestis MA.

Anal Bioanal Chem. 2013 Oct;405(26):8451-61. doi: 10.1007/s00216-013-7291-5. Epub 2013 Aug 17.

8.

Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration.

Lee D, Vandrey R, Milman G, Bergamaschi M, Mendu DR, Murray JA, Barnes AJ, Huestis MA.

Anal Bioanal Chem. 2013 Sep;405(23):7269-79. doi: 10.1007/s00216-013-7159-8. Epub 2013 Jul 6.

9.

Impact of oral fluid collection device on cannabinoid stability following smoked cannabis.

Anizan S, Bergamaschi MM, Barnes AJ, Milman G, Desrosiers N, Lee D, Gorelick DA, Huestis MA.

Drug Test Anal. 2015 Feb;7(2):114-20. doi: 10.1002/dta.1688. Epub 2014 Jul 3.

10.

Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration.

Swortwood MJ, Newmeyer MN, Andersson M, Abulseoud OA, Scheidweiler KB, Huestis MA.

Drug Test Anal. 2017 Jun;9(6):905-915. doi: 10.1002/dta.2092. Epub 2016 Oct 13.

PMID:
27647820
11.

Cannabinoids and metabolites in expectorated oral fluid following controlled smoked cannabis.

Milman G, Schwope DM, Gorelick DA, Huestis MA.

Clin Chim Acta. 2012 Apr 11;413(7-8):765-70. doi: 10.1016/j.cca.2012.01.011. Epub 2012 Jan 20.

12.

Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry.

Milman G, Barnes AJ, Lowe RH, Huestis MA.

J Chromatogr A. 2010 Feb 26;1217(9):1513-21. doi: 10.1016/j.chroma.2009.12.053. Epub 2010 Jan 4.

13.

Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration.

Schwope DM, Karschner EL, Gorelick DA, Huestis MA.

Clin Chem. 2011 Oct;57(10):1406-14. doi: 10.1373/clinchem.2011.171777. Epub 2011 Aug 11.

14.

Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users.

Lee D, Bergamaschi MM, Milman G, Barnes AJ, Queiroz RH, Vandrey R, Huestis MA.

J Anal Toxicol. 2015 Oct;39(8):580-7. doi: 10.1093/jat/bkv082.

15.

Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint.

Fabritius M, Chtioui H, Battistella G, Annoni JM, Dao K, Favrat B, Fornari E, Lauer E, Maeder P, Giroud C.

Anal Bioanal Chem. 2013 Dec;405(30):9791-803. doi: 10.1007/s00216-013-7412-1. Epub 2013 Nov 8.

PMID:
24202191
16.
17.

Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Δ(9)-tetrahydrocannabinol administration.

Milman G, Schwope DM, Schwilke EW, Darwin WD, Kelly DL, Goodwin RS, Gorelick DA, Huestis MA.

Clin Chem. 2011 Nov;57(11):1597-606. doi: 10.1373/clinchem.2011.169490. Epub 2011 Aug 29.

18.

Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC.

Karschner EL, Schwope DM, Schwilke EW, Goodwin RS, Kelly DL, Gorelick DA, Huestis MA.

Drug Alcohol Depend. 2012 Oct 1;125(3):313-9. doi: 10.1016/j.drugalcdep.2012.03.005. Epub 2012 Mar 29.

19.

Urinary cannabinoid disposition in occasional and frequent smokers: is THC-glucuronide in sequential urine samples a marker of recent use in frequent smokers?

Desrosiers NA, Lee D, Concheiro-Guisan M, Scheidweiler KB, Gorelick DA, Huestis MA.

Clin Chem. 2014 Feb;60(2):361-72. doi: 10.1373/clinchem.2013.214106. Epub 2013 Nov 1.

20.

Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers.

Newmeyer MN, Desrosiers NA, Lee D, Mendu DR, Barnes AJ, Gorelick DA, Huestis MA.

Drug Test Anal. 2014 Oct;6(10):1002-10. doi: 10.1002/dta.1632. Epub 2014 Mar 20.

Supplemental Content

Support Center